Plus de 40 ans d’expérience à votre service

Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr

Stock épuisé.
En rupture de stock
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte

 

 

100 µl

Ref. YIF-LF-MA0166
AB FRONTIER

photos non contractuelles

Neuf 331.00 H.T.

Quantité

Alerte réapprovisionnement
Recevez une alerte par email dès que votre choix sera de retour en stock
Votre e-mail*:

Détails Produit

Product description: Monoclonal Antibody. Recognizes the Human protein. Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol. alpha-1-antichymotrypsin (ACT) is a glycoprotein with a molecular weight of 55~68 kDa and 25% by weight of various sugars, whose heterogeneity results in variation of molecular weight. It inhibits chymotrypsin-like proteinases in vivo and has cytotoxic killer-cell activity in vitro. The protein also has a role as an acute-phase protein and is active in the control of immunologic and inflammatory processes, and as a tumor marker. Plasma ACT levels might increase rapidly more than 5-fold during an acute phase reaction, ACT has been shown to promote Abeta polymerization in vitro and in vivo, and levels of ACT protein in plasma and cerebrospinal fluid from Alzheimer's patients have been found to correlate with progression of dementia. Although its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2.

Alternate Names/Synonyms: AACT; GIG24; SERPINA3

Product Type: Monoclonal Antibody

Clone: 71A1

Isotype: Mouse IgG1 kappa

Immunogen: Protein purified from human plasma.

Applications: IHC, WB

Species Crossreactivity: Human

Formulation: Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.

Short Term Storage: +4°C

Long Term Storage: -20°C

Shipping: BLUE ICE

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.

Lien vers la Fiche Technique

Literature References: 1) Zhang S, Janciauskiene S. J Alzheimers Dis. (2002) vol.4(2): pp.115-22. (General)2) J, Levy M, Dickson DW, Brain. (2006) vol.129(Pt 11) : pp.3020-34. (General)